Pentacyclic active compound and conjugate thereof and use thereof

By designing pentacyclic active compounds and their conjugates, the problems of low drug loading rates and narrow treatment windows in targeted treatments have been solved, and more efficient and safe cancer-targeted treatment effects have been achieved.

WO2025040012A1PCT designated stage expired Publication Date: 2025-02-27CHENGDU CONMED BIOSCI CO LTD
View PDF 7 Cites 2 Cited by

Patent Information

Application Number
PCT/CN2024/112682
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-08-18
Filing Date
2024-08-16
Publication Date
2025-02-27

Smart Images

  • Figure CN2024112682_27022025_PF_FP_ABST
    Figure CN2024112682_27022025_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a pentacyclic active compound and a conjugate thereof and a use thereof. The compound and the conjugate have excellent tumor cell inhibition activity, stability and in vivo efficacy in animals.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Camptothecin derivative, preparation method therefor and application thereof

    WO2019238046A1

  • Prodrugs of CGRP antagonists

    WO2020077038A1

  • Camptothecin peptide conjugates

    CN111936169A

  • Bioactive conjugate, preparation method therefor and use thereof

    WO2019114666A1

  • Bioactive substance conjugate, preparation method therefor and use thereof

    WO2022170971A1

Cited By

  • Camptothecin compound and conjugate containing same and use thereof

    WO2025242097A1

  • Dosing regimens of antibody-drug conjugate targeting delta-like ligand 3 for treatment of neuroendocrine neoplasms

    WO2026086850A1